Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Catalyst Pharmaceuticals Inc Market Cap
The Catalyst Pharmaceuticals Inc (CPRX) share price is expected to increase by 46.46% over the next year. This is based on calculating the average 12-month share price estimate provided by 8 stock analysts who have covered CPRX. Price targets range from $28 at the low end to $38 at the high end. The current analyst consensus for CPRX is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Catalyst Pharmaceuticals Inc has a total of 8 Wall St Analyst ratings. There are 8 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Catalyst Pharmaceuticals Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of CPRX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Sudan Loganathan Stephens & Co. | Overweight | $35 | Initiates | Nov 18, 2024 |
| Joon Lee Truist Securities | Buy | $36 | Maintains | Nov 11, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $30 | Reiterates | Nov 8, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $30 | Maintains | Aug 12, 2024 |
| Joon Lee Truist Securities | Buy | $30 | Maintains | Aug 9, 2024 |
| Samantha Semenkow Citigroup | Buy | $31 | Maintains | Aug 9, 2024 |
| Leland Gershell Oppenheimer | Outperform | $29 | Reiterates | Jun 6, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $26 | Reiterates | Jun 3, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $26 | Maintains | May 10, 2024 |
| Leland Gershell Oppenheimer | Outperform | $29 | Reiterates | Mar 27, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $34 | Reiterates | Mar 22, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $34 | Reiterates | Mar 14, 2024 |
| Samantha Semenkow Citigroup | Buy | $27 | Initiates | Mar 14, 2024 |
| Jason Gerberry B of A Securities | Buy | $23 | Initiates | Mar 7, 2024 |
| Andrew Fein HC Wainwright & Co. | Buy | $24 | Reiterates | Mar 1, 2024 |
| Charles Duncan Cantor Fitzgerald | Overweight | $34 | Maintains | Mar 1, 2024 |
| Leland Gershell Oppenheimer | Outperform | $30 | Initiates | Dec 21, 2023 |
| Charles Duncan Cantor Fitzgerald | Overweight | $27 | Reiterates | Aug 22, 2023 |
| Charles Duncan Cantor Fitzgerald | Overweight | $27 | Maintains | Aug 11, 2023 |
| Andrew Fein HC Wainwright & Co. | Buy | $24 | Reiterates | Aug 11, 2023 |
When did it IPO
2006
Staff Count
167
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Richard John Daly M.B.A.
Market Cap
$2.63B
In 2023, CPRX generated $398.2M in revenue, which was a increase of 85.90% from the previous year. This can be seen as a signal that CPRX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 02 Dec 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Zacks Style Scores provide a method for investors to identify top-rated stocks tailored to their investment style, enhancing stock selection.
Why It Matters - Zacks Style Scores can help identify high-potential stocks tailored to specific investment strategies, enhancing decision-making and potentially improving portfolio performance.
Mon, 25 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The company reported a 234% revenue growth, attributing this success to operational excellence and strong commercial execution.
Why It Matters - 234% revenue growth signals strong company performance, indicating effective management and market demand. This can lead to increased investor confidence and potential stock price appreciation.
Wed, 27 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Zacks Style Scores can help investors identify strong, market-beating stocks for their portfolios.
Why It Matters - The Zacks Style Scores can help identify stocks with potential for strong performance, aiding investors in making informed decisions for their portfolios.
Fri, 22 Nov 2024
Sentiment - NEUTRAL
Source - Investors Business Daily
Summary - The top five biotech stocks currently share strong ratings, indicating favorable market performance and investor confidence.
Why It Matters - Strong ratings for top biotech stocks indicate investor confidence and potential for growth, signaling opportunities for profit in the biotech sector.
Tue, 19 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) announced that CEO Richard J. Daly and management will participate in upcoming investor conferences, focusing on rare disease treatments.
Why It Matters - Catalyst's participation in investor conferences highlights its commitment to engaging with investors, potentially influencing stock interest and market perception around its growth prospects.
Wed, 13 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Catalyst Pharmaceuticals has been named one of BioSpace's 2025 Best Places to Work, highlighting its status as a top employer in the life sciences sector.
Why It Matters - Catalyst Pharmaceuticals' recognition as a top workplace enhances its reputation, potentially attracting talent and boosting productivity, which can positively impact financial performance and stock value.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
